Lydia Scarfò Selected Research

Lydia Scarfò Research Topics

Disease

42	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 03/2024 - 05/2010
8	Neoplasms (Cancer) 11/2023 - 09/2013
5	COVID-19 11/2022 - 01/2020
5	Disease Progression 01/2022 - 11/2014
3	Residual Neoplasm 01/2023 - 12/2022
3	Lymphoma (Lymphomas) 01/2022 - 11/2015
2	Inflammation (Inflammations) 03/2024 - 10/2017
2	Infections 09/2022 - 01/2020
2	Lymphocytosis 01/2021 - 12/2018
2	Leukemia 01/2021 - 01/2018
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 03/2017 - 03/2015
2	Hematologic Neoplasms (Hematological Malignancy) 04/2016 - 09/2013
1	Psoriasis (Pustulosis Palmaris et Plantaris) 03/2024
1	Multiple Sclerosis 03/2024
1	Prostatic Neoplasms (Prostate Cancer) 11/2023
1	Melanoma (Melanoma, Malignant) 11/2023
1	Atrial Fibrillation 09/2022
1	Diarrhea 09/2022
1	Hemorrhage 01/2022
1	Thrombosis (Thrombus) 01/2022
1	Agammaglobulinemia (Hypogammaglobulinemia) 07/2021
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021
1	Mycoses (Diseases, Fungus) 01/2020
1	Invasive Fungal Infections 01/2020
1	Neoplasm Metastasis (Metastasis) 11/2019
1	Tissue Adhesions 01/2018
1	Melena 03/2017
1	Infarction (Infarctions) 03/2017
1	Vomiting 03/2017
1	Stroke (Strokes) 03/2017
1	Febrile Neutropenia 03/2017
1	Neutropenia 03/2017
1	Hypoxia (Hypoxemia) 04/2016

Drug/Important Bio-Agent (IBA)

13	ibrutinibIBA 03/2024 - 05/2018
8	Immunoglobulins (Immunoglobulin)IBA 11/2023 - 11/2014
6	Toll-Like Receptors (Toll-Like Receptor)IBA 03/2024 - 01/2013
6	venetoclaxIBA 10/2023 - 01/2021
4	Rituximab (Mabthera)FDA Link 11/2023 - 03/2015
3	Agammaglobulinaemia Tyrosine KinaseIBA 12/2022 - 01/2021
3	ofatumumab FDA Link 01/2022 - 12/2015
3	Oxygen (Dioxygen)IBA 01/2022 - 01/2020
3	Immunoglobulin M (IgM)IBA 01/2022 - 01/2014
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2023 - 12/2015
2	Transcription Factors (Transcription Factor)IBA 10/2023 - 04/2016
2	Messenger RNA (mRNA)IBA 11/2022 - 10/2021
2	BNT162 VaccineIBA 11/2022 - 10/2021
2	obinutuzumabIBA 01/2022 - 01/2020
2	Lenalidomide (CC 5013)FDA Link 01/2022 - 03/2017
2	Chlorambucil (Leukeran)FDA Link 01/2022 - 01/2020
2	Proteins (Proteins, Gene)FDA Link 11/2019 - 10/2017
2	ChemokinesIBA 10/2019 - 01/2018
1	Dimethyl FumarateIBA 03/2024
1	AntioxidantsIBA 03/2024
1	Glutathione (Reduced Glutathione)IBA 03/2024
1	fludarabineIBA 11/2023
1	dimethyl itaconateIBA 10/2023
1	Phosphotransferases (Kinase)IBA 01/2023
1	ribonucleotide polymeraseIBA 01/2023
1	AntigensIBA 01/2022
1	fibrin fragment D (D-dimer)IBA 01/2022
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2022
1	AlbuminsIBA 01/2022
1	Chimeric Antigen ReceptorsIBA 01/2022
1	C-Reactive ProteinIBA 01/2022
1	Antiviral Agents (Antivirals)IBA 01/2022
1	COVID-19 VaccinesIBA 10/2021
1	VaccinesIBA 07/2021
1	acalabrutinibIBA 01/2021
1	A-factor (Streptomyces)IBA 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	EpitopesIBA 01/2021
1	Cysteine (L-Cysteine)FDA Link 01/2021
1	Peptides (Polypeptides)IBA 01/2021
1	Complementarity Determining Regions (Complementarity Determining Region)IBA 01/2021
1	TrabectedinIBA 12/2019
1	Bendamustine Hydrochloride FDA Link 10/2019
1	idelalisibIBA 05/2018
1	RetinoidsIBA 01/2018
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2018
1	Chemokine CXCL13IBA 01/2018
1	Toll-Like Receptor 9IBA 11/2017
1	LigandsIBA 11/2017
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 10/2017
1	CalreticulinIBA 10/2017
1	Antigen Receptors (Antigen Receptor)IBA 10/2017
1	dinaciclibIBA 01/2017
1	Chromogranin AIBA 07/2016
1	Pentostatin (Nipent)FDA LinkGeneric 12/2015
1	Immunoglobulin G (IgG)IBA 01/2014
1	Immunoglobulin D (IgD)IBA 01/2014
1	Proto-Oncogene Proteins c-bcl-2 (Proto Oncogene Proteins c bcl 2)IBA 09/2013
1	MicroRNAs (MicroRNA)IBA 05/2010

Therapy/Procedure

10	Therapeutics 01/2023 - 09/2013
2	Immunotherapy 01/2021 - 01/2019
1	Duration of Therapy 09/2022
1	Palliative Care (Palliative Therapy) 11/2021
1	Critical Care (Surgical Intensive Care) 01/2020
1	Immunomodulation 12/2019
1	Stem Cell Transplantation 03/2017
1	Treatment Delay 08/2016